BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

PVLA upcoming catalysts

Palvella Therapeutics, Inc.: 0 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (0 Phase 3), 1 upcoming FDA decision event(s), and in the last 12 months 2 readout(s) and 0 FDA event(s). Subscribe to PVLA (.ics).

Upcoming FDA decision events

DateEventStatusCompanyDrugSource
2027-02-28PDUFA date (company-disclosed)pendingPALVELLA THERAPEUTICS, INC. PVLAPDUFA February 28, 2027 - PALVELLA THERAPEUTICS, INC.

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
No trials in this window.

FDA decision events, last 12 months

DateEventStatusCompanyDrugSource
No FDA decision events in this window.

Trial readouts, last 12 months

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-01-14P3Palvella Therapeutics, Inc. PVLANCT06239480 SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic MalformationsMicrocystic Lymphatic Malformationactive not recruiting51
2025-11-21P2Palvella Therapeutics, Inc. PVLANCT06653842 A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous MalformatioCutaneous Venous Malformationsactive not recruiting15

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.